Role of PI3K and EGFR in Oral Cancer Progression and Drug Resistance

Authors

  • Manzar Alam Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, INDIA.
  • Rajakishore Mishra Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, INDIA.

Keywords:

Oral Squamous Cell Carcinoma, OSCC, Oral cancer, drug resistance, PI3K, EGFR

Abstract

Oral cancer is one of the most common cancers in the world and India. Signaling molecules play an important role in Oral Squamous Cell Carcinoma (OSCC). PI3K and EGFR signaling molecules are known to be deregulation in most cancers including oral cancer. These are associated with oral cancer progression and drug resistance. PI3K and EGFR signalling molecules have been linked to the examined resistance developed to radiation and chemotherapy. Crucial signaling molecules that function downstream of the survival pathways, particularly at points where several of these pathways crosstalk that development oral cancer and drug resistance. The main focus of this review is to discuss the role and regulation of PI3K and EGFR in oral cancer drug resistance.

Downloads

Download data is not yet available.

References

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210

Kashyap, T., Pramanik, K. K., Nath, N., Mishra, P., Singh, A. K., Nagini, S., Rana, A., & Mishra, R. (2018). Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncology, 86, 234–243. https://doi.org/10.1016/j.oraloncology.2018.09.028

Parkin D. M. (2001). Global cancer statistics in the year 2000. The Lancet. Oncology, 2(9), 533–543. https://doi.org/10.1016/S1470-2045(01)00486-7

Pramanik, K. K., Singh, A. K., Alam, M., Kashyap, T., Mishra, P., Panda, A. K., Dey, R. K., Rana, A., Nagini, S., & Mishra, R. (2016). Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer. Tumor Biology, 37(11), 15253–15264. https://doi.org/10.1007/s13277-016-5362-x

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94(2), 153–156. https://doi.org/10.1002/ijc.1440

Alam, M., Kashyap, T., Mishra, P., Panda, A. K., Nagini, S., & Mishra, R. (2019). Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head & Neck, 41(1), 185–197. https://doi.org/10.1002/hed.25471

Sankaranarayanan, R., Ramadas, K., Thomas, G., Muwonge, R., Thara, S., Mathew, B., & Rajan, B. (2005). Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. The Lancet, 365(9475), 1927–1933. https://doi.org/10.1016/S0140-6736(05)66658-5

Alam, M., Kashyap, T., Pramanik, K. K., Singh, A. K., Nagini, S., & Mishra, R. (2017). The elevated activation of NFκB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clinical Oral Investigations, 21(9), 2721–2731. https://doi.org/10.1007/s00784-017-2074-6

Barasch, A., Safford, M., & Eisenberg, E. (1998). Oral cancer and oral effects of anticancer therapy. The Mount Sinai journal of medicine, New York, 65(5-6), 370–377.

Wang, C., Liu, X. Q., Hou, J. S., Wang, J. N., & Huang, H. Z. (2016). Molecular Mechanisms of Chemoresistance in Oral Cancer. The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA), 19(1), 25–33. https://doi.org/10.3290/j.cjdr.a35694

Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7(8), 573–584. https://doi.org/10.1038/nrc2167

Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007). The concurrent chemoradiation paradigm--general principles. Nature clinical practice. Oncology, 4(2), 86–100. https://doi.org/10.1038/ncponc0714

Wymann, M. P., Zvelebil, M., & Laffargue, M. (2003). Phosphoinositide 3-kinase signalling--which way to target?. Trends in pharmacological sciences, 24(7), 366–376. https://doi.org/10.1016/S0165-6147(03)00163-9

Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006). Signalling through Class I PI3Ks in mammalian cells. Biochemical Society transactions, 34(Pt 5), 647–662. https://doi.org/10.1042/BST0340647

Callaghan, T., Antczak, M., Flickinger, T., Raines, M., Myers, M., & Kung, H. J. (1993). A complete description of the EGF-receptor exon structure: implication in oncogenic activation and domain evolution. Oncogene, 8(11), 2939–2948.

Moore, S. R., Johnson, N. W., Pierce, A. M., & Wilson, D. F. (2000). The epidemiology of mouth cancer: a review of global incidence. Oral diseases, 6(2), 65–74. https://doi.org/10.1111/j.1601-0825.2000.tb00104.x

Georges, P., Rajagopalan, K., Leon, C., Singh, P., Ahmad, N., Nader, K., and Kubicek, G.J. (2014). Chemotherapy advances in locally advanced head and neck cancer. World Journal of Clinical Oncology, 5(5), 966. https://doi.org/10.5306/wjco.v5.i5.966

Cognetti, F., Pinnarö, P., Ruggeri, E. M., Carlini, P., Perrino, A., Impiombato, F. A., Calabresi, F., Chilelli, M. G., & Giannarelli, D. (1989). Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7(7), 829–837. https://doi.org/10.1200/JCO.1989.7.7.829

Bourhis, J., Wilson, G., Wibault, P., Janot, F., Bosq, J., Armand, J. P., Luboinski, B., Malaise, E. P., & Eschwege, F. (1994). Rapid Tumor Cell Proliferation After Induction Chemotherapy in Oropharyngeal Cancer: The Laryngoscope, 104(4), 468-472. https://doi.org/10.1288/00005537-199404000-00012

Belcher, R., Hayes, K., Fedewa, S., & Chen, A. Y. (2014). Current treatment of head and neck squamous cell cancer. Journal of surgical oncology, 110(5), 551–574. https://doi.org/10.1002/jso.23724

Mazeron, R., Tao, Y., Lusinchi, A., & Bourhis, J. (2009). Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral oncology, 45(4-5), 402–408. https://doi.org/10.1016/j.oraloncology.2009.01.010

Specenier, P. M., & Vermorken, J. B. (2009). Current concepts for the management of head and neck cancer: chemotherapy. Oral oncology, 45(4-5), 409–415. https://doi.org/10.1016/j.oraloncology.2008.05.014

Marsh, D., Suchak, K., Moutasim, K. A., Vallath, S., Hopper, C., Jerjes, W., Upile, T., Kalavrezos, N., Violette, S. M., Weinreb, P. H., Chester, K. A., Chana, J. S., Marshall, J. F., Hart, I. R., Hackshaw, A. K., Piper, K., & Thomas, G. J. (2011). Stromal features are predictive of disease mortality in oral cancer patients. The Journal of pathology, 223(4), 470–481. https://doi.org/10.1002/path.2830

Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008). Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica et biophysica acta, 1784(1), 159–185. https://doi.org/10.1016/j.bbapap.2007.10.003

Scheid, M. P., & Woodgett, J. R. (2003). Unravelling the activation mechanisms of protein kinase B/Akt. FEBS letters, 546(1), 108–112. https://doi.org/10.1016/s0014-5793(03)00562-3

Li, N., Sui, J., Liu, H., Zhong, M., Zhang, M., Wang, Y., & Hao, F. (2015). Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma. International journal of clinical and experimental medicine, 8(4), 5236–5244.

Yu, Z., Weinberger, P. M., Sasaki, C., Egleston, B. L., Speier, W. F., Haffty, B., Kowalski, D., Camp, R., Rimm, D., Vairaktaris, E., Burtness, B., & Psyrri, A. (2007). Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention, 16(3), 553–558. https://doi.org/10.1158/1055-9965.EPI-06-0121

Iamaroon, A., & Krisanaprakornkit, S. (2009). Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncology, 45(10), e175–e179. https://doi.org/10.1016/j.oraloncology.2009.06.003

Song, G., Ouyang, G., & Bao, S. (2005). The activation of Akt/PKB signaling pathway and cell survival. Journal of cellular and molecular medicine, 9(1), 59–71. https://doi.org/10.1111/j.1582-4934.2005.tb00337.x

Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science (New York, N.Y.), 282(5392), 1318–1321. https://doi.org/10.1126/science.282.5392.1318

Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 25(51), 6800–6816. https://doi.org/10.1038/sj.onc.1209938

Gupta, A. K., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., Bernhard, E. J., Weber, R. S., & Muschel, R. J. (2002). Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clinical cancer research : an official journal of the American Association for Cancer Research, 8(3), 885–892.

Li, Q., & Verma, I. M. (2002). NF-kappaB regulation in the immune system. Nature reviews. Immunology, 2(10), 725–734. https://doi.org/10.1038/nri910

Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401(6748), 82–85. https://doi.org/10.1038/43466

Downward J. (2004). PI 3-kinase, Akt and cell survival. Seminars in cell & developmental biology, 15(2), 177–182. https://doi.org/10.1016/j.semcdb.2004.01.002

Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews. Molecular cell biology, 2(2), 127–137. https://doi.org/10.1038/35052073

Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366(1), 2–16. https://doi.org/10.1016/j.gene.2005.10.018

Rabinowits, G., & Haddad, R. I. (2012). Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral oncology, 48(11), 1085–1089. https://doi.org/10.1016/j.oraloncology.2012.06.016

Fung, C., & Grandis, J. R. (2010). Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert opinion on emerging drugs, 15(3), 355–373. https://doi.org/10.1517/14728214.2010.497754

Grandis, J. R., & Sok, J. C. (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacology & therapeutics, 102(1), 37–46. https://doi.org/10.1016/j.pharmthera.2004.01.002

Soh, J. W., Lee, E. H., Prywes, R., & Weinstein, I. B. (1999). Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Molecular and cellular biology, 19(2), 1313–1324. https://doi.org/10.1128/mcb.19.2.1313

Johnson D. E. (2012). Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chinese journal of cancer, 31(7), 319–326. https://doi.org/10.5732/cjc.011.10404

Laimer, K., Spizzo, G., Gastl, G., Obrist, P., Brunhuber, T., Fong, D., Barbieri, V., Jank, S., Doppler, W., Rasse, M., & Norer, B. (2007). High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncology, 43(2), 193–198. https://doi.org/10.1016/j.oraloncology.2006.02.009

Modjtahedi, H., & Essapen, S. (2009). Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-cancer drugs, 20(10), 851–855. https://doi.org/10.1097/CAD.0b013e3283330590

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210

Downloads

Published

2020-11-30

How to Cite

Manzar Alam, & Rajakishore Mishra. (2020). Role of PI3K and EGFR in Oral Cancer Progression and Drug Resistance. International Journal for Research in Applied Sciences and Biotechnology, 7(6), 85–89. Retrieved from https://ijrasb.com/index.php/ijrasb/article/view/300

Issue

Vol. 7 No. 6 (2020): November Issue

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.